Possible association between toxoplasma gondii infection and schizophrenia: Egyptian study

Infectious Diseases in Clinical Practice

Volumn 20, Issue 6, 2012, Pages 394-399

  El Sayed, Nagwa Mostafa ^a   Ismail, Khadiga Ahmed ^b   Ahmed, Sabah Abd El Ghany ^b   Ezz El Din, Hayam Mohamed ^b   Ezz El Din Azzam, Hanan Mohamed E ^b  

^a RESEARCH INSTITUTE OF OPHTHALMOLOGY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

anti T. gondii IgG; enzyme linked immunosorbent assay; schizophrenia; sICAM 1; Toxoplasma gondii

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DSM-IV; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; SCHIZOPHRENIA; SEROLOGY; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 84870246902     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31826991aa     Document Type: Article

References (54)

1. Pusch L, Romeike B, Deckert M, et al. Persistent Toxoplasma bradyzoite cysts in the brain: incidental finding in an immunocompetent patient without evidence of a toxoplasmosis. Clin Neuropathol. 2009;28:210-212.
2. Henriquez SA, Brett R, Alexander J, et al. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009;16:122-133.
3. Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003;9(11):1375-1380.
4. Cetinkaya Z, Yazar S, Gecici O, et al. Anti-Toxoplasma gondii antibodies in patients with schizophreniaVpreliminary findings in a Turkish sample. Schizophr Bull. 2007;33(3):789-791.
5. Leweke FM, Gerth CW, Koethe D, et al. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254:4-8.
6. Yolken RH, Bachmann S, Rouslanova I, et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis. 2001;32:842-844.
7. Havlicek J, Gašová Z, Smith AP, et al. Decrease of psychomotor performance in subjects with latent 'asymptomatic' toxoplasmosis. Parasitology. 2001;122:515-520.
8. Creuzet C, Robert F, Roisin MP, et al. Neurons in primary cultures are less efficiently infected by Toxoplasma gondii than glial cells. Parasitol Res. 1998;84(1):25-30.
9. Halonen SK, Lyman WD, Chiu FC. Growth and development of Toxoplasma gondii in human neurons and astrocytes. J Neuropathol Exp Neurol. 1996;55(11):1150-1156.
10. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull. 2001; 55:585-595.
11. Doyle C, Deakin JFW. Fewer astrocytes in frontal cortex in schizophrenia, depression and bipolar disorder [abstract]. Schizophr Res. 2002;53:106.
12. Gaskell EA, Smith JE, Pinney JW, et al. A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS ONE. 2009;4(3):e4801.
13. Melamede R. Parasitic brain infection, endocannabinoids, and schizophrenia. Med Hypotheses. 2009; 72:220-222.
14. Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut. 1995;36:604-609.
15. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet. 1991;338:83-84.
16. Rothlein R, Mainolfi EA, Czakowski M, et al. A form of circulating ICAM-1 in human serum. J Immunol. 1991;147:3788-3793.
17. Lachenmaier SM, Deli MA, Meissner M, et al. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. J Neuroimmunol. 2011;232(1-2):119-130.
18. Deckert-Schulter M, Schulter D, Hof H, et al. Differential expression of ICAM-1, VCAM-1 and their ligands LFA-1, Mac-1, CD4, VLA-4 and MHC class II antigens in murine Toxoplasma encephalitis: a light microscopic and ultrastructural immunohistochemical study. J Neuropathol Exp Neurol. 1994;53(5):547-568.
19. Nagineni CN, Detrick B, Hooks JJ. Toxoplasma gondii infection induces gene expression and secretion of interleukin 1 (IL-1), IL-6, granulocyte-macrophage colony, and intracellular adhesion molecule-1 by human retinal pigment epithelial cells. Infect Immunol. 2000;68(1):407-410.
20. Fekadu A, Shibre T, Cleare AJ. Toxoplasmosis as a cause for behaviour disordersVoverview of evidence and mechanisms. Folia Parasitol. 2010;57(2):105-113.
21. Brown AS, Vinogradov S, Kremen WS, et al. Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. Am J Psychiatry. 2009;166(6):683-690.
22. Yolken RH, Dickerson FB, Fuller Torrey E. Review: Toxoplasma and schizophrenia. Parasite Immunol. 2009;31:706-715.
23. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965- 1976.
24. Daubener W, Hadding U. Cellular immune reactions directed against Toxoplasma gondii with special emphasis on the central nervous system. Med Microbiol Immunol. 1997;185:195-206.
25. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry. 2000;48:327-329.
26. Tamer GS, Dundar D, Yalug I, et al. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Adv Ther. 2008;25(7):703-709.
27. Hamidinejat H, Ghorbanpoor M, Hosseini H, et al. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis. 2010;14(11):e978-e981.
28. Ahmad D, Mehdi S, Sayed HH, et al. Serological survey of Toxoplasma gondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed. 2010;27(3):476-482.
29. Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, et al. Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 2011;60(2):151-155.
30. Tedla Y, Shibre T, Ali O, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop Med J. 2011;49(3):211-220.
31. Wang HL, Wang GH, Li QY, et al. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 2006;114:40-48.
32. Grigg ME, Bonnefoy S, Hehl AB, et al. Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestries. Science. 2001;294:161-165.
33. Torrey EF, Bartko JJ, Lun Z, et al. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(3):729-736.
34. Kadl A, Leitinger N. The role of endothelial cells in the resolution of acute inflammation. Antioxid Redox Signal. 2005;7(11-12):1744-1754.
35. Coisne C, Faveeuw C, Delplace Y, et al. Differential expression of selectins by mouse brain capillary endothelial cells in vitro in response to distinct inflammatory stimuli. Neurosci Lett. 2006;392(3):216-220.
36. Fabry Z, Waldschmidt MM, Hendrickson D, et al. Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55. J Neuroimmunol. 1992;36:1-11.
37. Héry C, Sébire G, Peudenier S, et al. Adhesion to human neurons and astrocytes of monocytes: the role of interaction of CR3 and ICAM-1 and modulating by cytokines. J Neuroimmunol. 1995;57:101-109.
38. Rieckmann P, Michel U, Albrecht M, et al. Cerebral endothelial cells are a major source for soluble intercellular adhesion molecule-1 in the human central nervous system. Neurosci Lett. 1995;186(1):61-64.
39. Champagne B, Tremblay P, Cantin A, et al. Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol. 1998;161:6398-6405.
40. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1):an overview. Eur Cytokine Netw. 2004;15:91-98.
41. Barragan A, Brossier F, Sibley LD. Transepithelial migration of Toxoplasma gondii involves an interaction of intercellular adhesion molecule 1 (ICAM-1) with the parasite adhesin MIC2. Cell Microbiol. 2005;7(4):561-568.
42. Barragan A, Sibley LD. Migration of Toxoplasma gondii across biological barriers. Trends Microbiol. 2003;11(9):426-430.
43. Deckert-Schlüter M, Bluethmann H, Kaefer N, et al. Interferon-F receptor-mediated but not tumor necrosis factor receptor type 1-or type 2-mediated signaling is crucial for the activation of cerebral blood vessel endothelial cells and microglia in murine Toxoplasma encephalitis. Am J Pathol. 1999;154(5):1549-1561.
44. Pfaff AW, Georges S, Abou-Bacar A, et al. Toxoplasma gondii regulates ICAM-1-mediated monocyte adhesion to trophoblasts. Immunol Cell Biol. 2005;83:483-489.
45. Silva NM, Manzan RM, Carneiro WP, et al. Toxoplasma gondii: the severity of toxoplasmic encephalitis in C57BL/6 mice is associated with increased ALCAM and VCAM-1 expression in the central nervous system and higher blood-brain barrier permeability. Exp Parasitol. 2010;126(2):167-177.
46. Rieckmann P, Nunke K, Burchardt M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol. 1993;47(2):133-140.
47. Ben-Shachar D, Livne E, Spanier I, et al. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J Neurochem. 1994;62:1112-1118.
48. Müller N, Ackenheil M. Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophr Res. 1995;14:223-228.
49. +) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011. Schizophr Res. 1998;32:69-71.
50. Müller N, Hadjamu M, Riedel M, et al. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry. 1999;156:634-636.
51. Schwarz MJ, Riedel M, Ackenheil M, et al. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry. 2000;47(1):29-33.
52. Müller N, Ackenheil M, Hofschuster E, et al. Cellular immunity in schizophrenic patients before and during neuroleptic therapy. Psychiatry Res. 1991;37:147-160.
53. Rothermund M, Arolt V, Weitzsch C, et al. Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry. 1996;40:1294-1297.
54. Russo R, Ciminale M, Ditommaso S, et al. Hepatitis B vaccination in psychiatric patients. Lancet. 1994;343:356.